Investigational drug · Phase 3
Retatrutide
Also called: LY3437943
Not approved by FDA. In 16 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight, Type 2 Diabetes.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
16
10 still active
All registered trials
33
Any phase or sponsor naming "Retatrutide"
First trial start
2023
May 30, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Retatrutide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Overweight
- Type 2 Diabetes
- Obstructive Sleep Apnea
- Diabetes Mellitus, Type 2
- Chronic Low Back Pain (CLBP)
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Chronic Kidney Disease (CKD)
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Diabetes Type 2
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Chronic kidney disease · Cardiovascular and metabolic · Kidney and urology · Gastroenterology and liver · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "Retatrutide" as an intervention, largest first.
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Pivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06383390 · 10,000 participants (planned) · Start Apr 30, 2024 · Primary completion Feb 2029
Drug: Retatrutide; Placebo · For: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)
Sites: Alabaster, Alabama; Birmingham, Alabama; Daphne, Alabama · 742 sites in all
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07165028 · 4,500 participants (planned) · Start Oct 15, 2025 · Primary completion Aug 2030
Drug: Tirzepatide; Retatrutide and 1 more · For: Metabolic Dysfunction-Associated Steatotic Liver Disease
Sites: Tuscaloosa, Alabama; Chandler, Arizona; Gilbert, Arizona · 563 sites in all
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05929066 · 2,335 participants · Start Jul 10, 2023 · Primary completion Apr 6, 2026
Drug: Retatrutide; Placebo · For: Obesity; Overweight; Osteoarthritis, Knee and 1 more
Sites: Phoenix, Arizona; Little Rock, Arkansas; Fresno, California · 134 sites in all
- A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseasePivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05882045 · 1,946 participants · Start May 30, 2023 · Primary completion Apr 16, 2026
Drug: Retatrutide; Placebo · For: Obesity; Cardiovascular Diseases
Sites: Phoenix, Arizona; Covina, California; Fresno, California · 169 sites in all
- Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)Pivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06260722 · 1,250 participants (planned) · Start Feb 21, 2024 · Primary completion Aug 27, 2026
Drug: Retatrutide; Semaglutide · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Escondido, California; Long Beach, California · 77 sites in all
- A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05929079 · 1,152 participants · Start Jul 11, 2023 · Primary completion Jun 16, 2026
Drug: Retatrutide; Placebo · For: Type 2 Diabetes; Obesity; Overweight and 1 more
Sites: Anniston, Alabama; Cullman, Alabama; Little Rock, Arkansas · 98 sites in all
- A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06662383 · 800 participants (planned) · Start Nov 1, 2024 · Primary completion Nov 2026
Drug: Retatrutide; Tirzepatide · For: Obesity
Sites: Tempe, Arizona; Newport Beach, California; San Diego, California · 65 sites in all
- A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06859268 · 643 participants (planned) · Start Mar 5, 2025 · Primary completion Apr 2028
Drug: Retatrutide; Placebo · For: Obesity
Sites: Santa Ana, California; Aurora, Colorado; Hamden, Connecticut · 53 sites in all
- A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07357415 · 600 participants (planned) · Start Jan 24, 2026 · Primary completion Oct 2028
Drug: Retatrutide · For: Obesity; Overweight
Sites: Phoenix, Arizona; Huntington Beach, California; Los Angeles, California · 35 sites in all
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07035093 · 586 participants (planned) · Start May 29, 2025 · Primary completion Sep 2027
Drug: Retatrutide; Placebo · For: Obesity; Overweight; Chronic Low Back Pain (CLBP)
Sites: Chandler, Arizona; Tucson, Arizona; Fountain Valley, California · 40 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
Carneiro GRA, da Costa Nunes IK, Dos Santos Cardoso GR, et al. · Rapid Commun Mass Spectrom 2026
- GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases.
Koceva E, Moll GN · Eur J Pharmacol 2026
- The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.
Chen Z, Zhou Y, Li G, et al. · J Diabetes Metab Disord 2026
- Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Amjad MM, Khan MM, Sarwar F, et al. · Diabetes Obes Metab 2026
- Next-generation incretin therapeutics for polyendocrine metabolic ovarian syndrome: navigating current pipeline and clinical considerations.
Ozgen Saydam B, Yldz BO · Expert Opin Pharmacother 2026
- Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity.
Schnitzer TJ, Hunter DJ, Conaghan PG, et al. · N Engl J Med 2026
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.